Erica Bonazzina
Overview
Explore the profile of Erica Bonazzina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roazzi L, Patelli G, Bencardino K, Amatu A, Bonazzina E, Tosi F, et al.
Clin Colorectal Cancer
. 2024 Mar;
23(4):295-308.
PMID: 38519391
Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular...
2.
Mauri G, Patelli G, Roazzi L, Valtorta E, Amatu A, Marrapese G, et al.
J Clin Pathol
. 2024 Feb;
78(3):195-201.
PMID: 38350716
Background: Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, gene copy number loss ( loss) confers a selective dependency on the...
3.
Patelli G, Mauri G, Tosi F, Amatu A, Bencardino K, Bonazzina E, et al.
Clin Cancer Res
. 2023 Jul;
29(22):4530-4539.
PMID: 37436743
In the evolving molecular treatment landscape of metastatic colorectal cancer (mCRC), the identification of druggable alterations is pivotal to achieve the best therapeutic opportunity for each patient. Because the number...
4.
Mauri G, Pedrani M, Ghezzi S, Bencardino K, Mariano S, Bonazzina E, et al.
BMJ Support Palliat Care
. 2023 Jun;
13(e3):e885-e889.
PMID: 37344158
Objectives: Early-onset colorectal cancer (EO-CRC) incidence is increasing, raising a clinical challenge. Clinicians tend to treat EO-CRC patients with more intensive regimens despite the lack of survival benefits, based on...
5.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, et al.
Front Oncol
. 2023 Apr;
13:1147497.
PMID: 37056342
[This corrects the article DOI: 10.3389/fonc.2022.1030232.].
6.
Mauri G, Patelli G, Gori V, Lauricella C, Mussolin B, Amatu A, et al.
Front Oncol
. 2022 Nov;
12:1030232.
PMID: 36419886
Background: We aim to identify the prevalence and the role of the mutation in predicting resistance to anti-EGFR agents in metastatic colorectal cancer (mCRC) patients. Methods: We retrospectively reviewed tumor-based...
7.
Amatu A, Mauri G, Tosi F, Bencardino K, Bonazzina E, Gori V, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267504
Background: oxaliplatin with fluoropyrimidine is a "mainstay" regarding the upfront treatment of metastatic colorectal cancer (mCRC). In contrast, the efficacy and safety of oxaliplatin-based regimens in late-care settings have been...
8.
Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, et al.
Target Oncol
. 2021 Mar;
16(3):413.
PMID: 33788137
No abstract available.
9.
Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, et al.
Target Oncol
. 2021 Mar;
16(3):309-324.
PMID: 33738696
Liquid biopsy recently gained widespread attention as a noninvasive alternative/complementary technique to tissue biopsy in patients with cancer. As technological advances have improved both feasibility and turnaround time, liquid biopsy...
10.
Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, et al.
Cancers (Basel)
. 2021 Jan;
13(1).
PMID: 33406649
The mutation is found in 8-10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months....